These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 16581171)

  • 1. New-onset type-2 diabetes associated with atypical antipsychotic medications.
    Lambert MT; Copeland LA; Sampson N; Duffy SA
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):919-23. PubMed ID: 16581171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients.
    Aparasu RR; Jano E; Johnson ML; Chen H
    Am J Geriatr Pharmacother; 2008 Oct; 6(4):198-204. PubMed ID: 19028375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of study design on the results of pharmacoepidemiologic studies of diabetes risk with antipsychotic therapy.
    Gianfrancesco F; Wang RH; Nasrallah HA
    Ann Clin Psychiatry; 2006; 18(1):9-17. PubMed ID: 16517448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database.
    Gianfrancesco F; White R; Wang RH; Nasrallah HA
    J Clin Psychopharmacol; 2003 Aug; 23(4):328-35. PubMed ID: 12920407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.
    Morrato EH; Druss B; Hartung DM; Valuck RJ; Allen R; Campagna E; Newcomer JW
    Arch Gen Psychiatry; 2010 Jan; 67(1):17-24. PubMed ID: 20048219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.
    Guo JJ; Keck PE; Corey-Lisle PK; Li H; Jiang D; Jang R; L'Italien GJ
    Pharmacotherapy; 2007 Jan; 27(1):27-35. PubMed ID: 17192159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The implications of weight changes with antipsychotic treatment.
    Sussman N
    J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S21-6. PubMed ID: 12832946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among Central Texas veterans.
    Barner JC; Worchel J; Yang M
    Pharmacotherapy; 2004 Nov; 24(11):1529-38. PubMed ID: 15537558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors.
    Sankaranarayanan J; Puumala SE
    Clin Ther; 2007 Apr; 29(4):723-41. PubMed ID: 17617297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors related to antipsychotic oversupply among Central Texas Veterans.
    Yang M; Barner JC; Worchel J
    Clin Ther; 2007 Jun; 29(6):1214-25. PubMed ID: 17692735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and characteristics of emergency departments visits by US adults with psychiatric disorder and antipsychotic mention from 2000 to 2004.
    Sankaranarayanan J; Puumala SE
    Curr Med Res Opin; 2007 Jun; 23(6):1375-85. PubMed ID: 17594776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
    McIntyre RS; Jerrell JM
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal glucose metabolism in patients treated with antipsychotics.
    Scheen AJ; De Hert MA
    Diabetes Metab; 2007 Jun; 33(3):169-75. PubMed ID: 17412628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study.
    Hrdlicka M; Zedkova I; Blatny M; Urbanek T
    Neuro Endocrinol Lett; 2009; 30(2):256-61. PubMed ID: 19675512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of second generation antipsychotics on leptin and ghrelin.
    Esen-Danaci A; Sarandöl A; Taneli F; Yurtsever F; Ozlen N
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1434-8. PubMed ID: 18579280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events in children and adolescents treated with antipsychotic medications.
    Jerrell JM; McIntyre RS
    Hum Psychopharmacol; 2008 Jun; 23(4):283-90. PubMed ID: 18302312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.
    Morrato EH; Cuffel B; Newcomer JW; Lombardo I; Kamat S; Barron J
    J Clin Psychopharmacol; 2009 Feb; 29(1):26-32. PubMed ID: 19142103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of monitoring for glucose and lipid dysregulation in adult Medi-Cal patients newly started on antipsychotics.
    Barnett M; VonMuenster S; Wehring H; Popish S; McDonald K; Walker VM; Perry P
    Ann Clin Psychiatry; 2010 Feb; 22(1):9-18. PubMed ID: 20196978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clozapine-induced type-2 diabetes mellitus: possible mechanisms and implications for clinical practice.
    Tovey E; Rampes H; Livingstone C
    J Psychopharmacol; 2005 Mar; 19(2):207-10. PubMed ID: 15728442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.